Leptomeningeal Metastases (LM) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 Leptomeningeal metastases are defined as the spread of the disease to the meninges surrounding the brain and the spinal cord and a rare but frequently devastating complication of advanced cancer. When cancer cells are found in your leptomeninges or CSF, this is called leptomeningeal metastases (LM). LM stick onto nerves as they exit your brain and spinal cord, causing weakness and numbness. LM can also clog your leptomeninges and prevent CSF from being drained properly, causing CSF and pressure to build up inside of your brain. LC is diagnosed in approximately 5% of patients with advanced cancer. However, in autopsy studies, it can be detected in up to 20% of cases. LC is most frequently associated with breast cancer, lung cancer, melanoma, gastrointestinal cancer, and cancer of unknown primary. also, be detected in primary brain tumors and hematologic malignancies. The prognosis of LC is poor, with median survival ranging from 4–6 weeks when untreated to 2–3 months when treated. Current treatment strategies include radiotherapy, systemic antineoplastic agents, and intrathecal chemotherapy.

The competitive landscape of Leptomeningeal Metastases (LM) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Leptomeningeal Metastases (LM) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Leptomeningeal Metastases (LM) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Leptomeningeal Metastases (LM) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          radiolabeled DPTA-omburtamab Y-mAbs Therapeutics    Phase 2

2          186RNL            Plus Therapeutics          Phase 1

3          Tesevatinib       Kadmon Corporation, LLC         Phase 2

4          Pembrolizumab Merck Sharp & Dohme Corp.     Phase 2

5          Bevacizumab    Genentech, Inc. Phase 2

6          Avelumab         Pfizer    Phase 1

7          ANG1005          Angiochem Inc  Phase 3

8          Trastuzumab deruxtecan           Daiichi Sankyo, Inc.       Phase 2

9          AZD3759          AstraZeneca     Phase 1

10        Trastuzumab     Hoffmann-La Roche      Phase 2